TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer
Status:
Completed
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL) has achieved
impressive clinical results with durable complete responses in patients with metastatic
melanoma. Recently, the investigators have completed a pilot study treating 6 patients with
metastatic ovarian cancer. The TILs are isolated from patients own tumor tissue followed by
in vitro expansion and activation for around 4-6 weeks. Before TIL infusion the patients
receive 1 week of preconditioning chemotherapy with cyclophosphamide and fludarabine. After
TIL infusion Interleukin-2 is administered to support T cell activation and proliferation in
vivo.
The investigators recent pilot study has shown TIL therapy in patients with metastatic
ovarian cancer to be feasible and tolerable. Mainly transient clinical responses where
observed and therefore the investigators plan to combine TIL therapy with checkpoint
inhibitors to potentially increase the clinical effect.